ChromaDex (CDXC) Expected to Announce Earnings on Tuesday

ChromaDex (NASDAQ:CDXC) is anticipated to release its earnings data after the market closes on Tuesday, March 4th. Analysts expect ChromaDex to post earnings of $0.02 per share and revenue of $26.51 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

ChromaDex Stock Performance

Shares of NASDAQ CDXC opened at $5.64 on Friday. ChromaDex has a 52 week low of $1.57 and a 52 week high of $7.97. The stock has a market capitalization of $430.80 million, a P/E ratio of 564.56 and a beta of 2.21. The stock’s fifty day moving average is $5.61 and its 200 day moving average is $5.05.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 9.64% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on CDXC. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 24th. Roth Mkm raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.